Retinitis Pigmentosa Clinical Trial
OBJECTIVES: I. Examine the concentration of docosahexanoic acid (DHA) and other n-3 fatty
acids in plasma, erythrocyte, and adipose tissue in patients with various forms of retinitis
pigmentosa and Usher syndrome.
II. Determine the synthesis and catabolism of DHA from linolenic acid in these patients.
III. Determine the synthesis, absorption, and catabolism of DHA under different dietary
conditions in these patients.
PROTOCOL OUTLINE: Patients may participate in one or more of the arms of this study.
Arm I (adipose tissue study): Adipose tissue is collected from the buttocks of patients with
Usher II retinitis pigmentosa (RP), patients with non-Usher RP, and control subjects.
Dietary histories are obtained from all patients and subjects.
Arm II (isotope study): Patients meeting the same criteria as in arm I receive oral
D5-labeled linolenic acid and oral D4-labeled linolenic acid that is dissolved in oil and
incorporated into foods. Subjects must avoid eating fish and shellfish during the 35 days of
the isotope study. Blood samples are collected at 0, 8, 24, and 48 hours, daily on days 3-7,
and then on days 10, 18, and 35.
Arm III (flaxseed oil feeding): Patients with all types of RP and control subjects receive
flaxseed oil, a form of linolenic acid, for 12 weeks. Subjects may also receive high oleic
safflower oil or olive oil as a control fat for 12 weeks. Subjects complete a diet history
at the end of each fatty acid supplementation period. All subjects must follow a diet free
of seafood and fish oil supplements.
;
Primary Purpose: Screening
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01432847 -
Cell Collection to Study Eye Diseases
|
||
| Completed |
NCT04983914 -
Retrospective NIS to Evaluate the Patient Benefit of TES
|
||
| Recruiting |
NCT03845218 -
Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
|
||
| Completed |
NCT00231010 -
Molecular Genetics of Retinal Degenerations
|
||
| Active, not recruiting |
NCT04611503 -
PDE6A Gene Therapy for Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
| Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
| Recruiting |
NCT01914913 -
Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
| Completed |
NCT01949623 -
Biomarkers In Retinitis Pigmentosa (BIRP)
|
N/A | |
| Completed |
NCT01835002 -
Transcorneal Electrical Stimulation - Multicenter Safety Study
|
N/A | |
| Completed |
NCT00407602 -
Argus® II Retinal Stimulation System Feasibility Protocol
|
N/A | |
| Completed |
NCT00515814 -
Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors
|
N/A | |
| Completed |
NCT00100230 -
DHA and X-Linked Retinitis Pigmentosa
|
Phase 2 | |
| Active, not recruiting |
NCT00378742 -
Repository for Inherited Eye Diseases
|
||
| Terminated |
NCT05085964 -
An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
|
Phase 2 | |
| Recruiting |
NCT05805007 -
Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa
|
Early Phase 1 | |
| Recruiting |
NCT06291935 -
Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene
|
Phase 1 | |
| Recruiting |
NCT05909488 -
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03078309 -
The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients
|
Early Phase 1 | |
| Completed |
NCT04238858 -
Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa
|
N/A | |
| Active, not recruiting |
NCT01680510 -
The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil
|
Phase 1/Phase 2 |